Abstract
Background. Treatment with a single donor-specific transfusion (DST) plus a brief course of anti-CD154 monoclonal antibody (mAb) prolongs skin allograft survival in mice. It is known that prolongation of allograft survival by this method depends in part on deletion of alloreactive CD8+ T cells at the time of tolerance induction. Recent data suggest that infection with lymphocytic choriomeningitis virus (LCMV) abrogates the ability of this protocol to prolong graft survival. Methods. To study the mechanism by which viral infection abrogates allograft survival, we determined (1) the fate of tracer populations of alloreactive transgenic CD8+ T cells and (2) the duration of skin allograft survival following treatment with DST and anti-CD154 mAb in the presence or absence of LCMV infection. Results. We confirmed that treatment of uninfected mice with DST and anti-CD154 mAb leads to the deletion of alloreactive CD8+ T cells and is associated with prolongation of skin allograft survival. In contrast, treatment with DST and anti-CD154 mAb in the presence of intercurrent LCMV infection was associated with the failure to delete alloreactive CD8+ T cells and with the rapid rejection of skin allografts. The number of alloreactive CD8+ cells actually increased significantly, and the cells acquired an activated phenotype. Conclusions. Interference with the deletion of allo-reactive CD8+ T cells mediated by DST and anti-CD154 mAb may in part be the mechanism by which viral infection abrogates transplantation tolerance induction. (C) 2000 Academic Press.
Original language | English (US) |
---|---|
Pages (from-to) | 63-69 |
Number of pages | 7 |
Journal | Journal of Surgical Research |
Volume | 93 |
Issue number | 1 |
DOIs | |
State | Published - 2000 |
Externally published | Yes |
Bibliographical note
Funding Information:Presented at the Annual Meeting of the Association for Academic Surgery, Philadelphia, Pennsylvania, November 18–20, 1999. Supported in part by Program Projects 1PO1-DK53006 and 1PO1-AI42669, Center Grant DK32520, and RO1-AR35506 (RMW) from the National Institutes of Health. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. We thank Keith A. Daniels for technical assistance.
Keywords
- CD154
- CD40
- LCMV
- Tolerance
- Transplantation
- Virus